Department of Pathology, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Cancer Immunol Immunother. 2021 May;70(5):1365-1378. doi: 10.1007/s00262-020-02776-5. Epub 2020 Nov 4.
Myeloid-derived suppressor cells (MDSCs) play an important role in tumor progression through both immunologic and non-immunologic mechanisms. This study was conducted to evaluate the expression of S100A8, a well-known MDSC marker, and the significance of its expression in pre-invasive and invasive breast cancers. S100A8 expression in tumor cells (TCs) and immune cells (ICs) was assessed by immunohistochemistry, and its association with clinicopathologic features and infiltration of other IC subsets including CD4+, CD8+, and FOXP3+ tumor-infiltrating lymphocytes (TILs) and PD-L1+ ICs was evaluated. S100A8 expression in TCs and ICs showed a positive correlation in pre-invasive carcinoma and invasive carcinoma. S100A8+ ICs, but not S100A8+ TCs, were significantly higher in number in invasive carcinoma than in pre-invasive carcinoma. Infiltration of S100A8+ ICs was revealed as a poor prognostic indicator in pre-invasive and invasive carcinomas, especially in hormone receptor-positive subgroup. Infiltration of CD4+, CD8+, and FOXP3+ TIL subsets and PD-L1+ ICs was significantly higher in S100A8+ IC (+) group than in S100A8+ IC (-) group. Combined analyses of IC subset infiltration revealed that infiltration of S100A8+ ICs was associated with poor clinical outcome in the PD-L1+ IC (-), CD8+ TIL-low, and FOXP3+ TIL-low subgroups. In conclusion, S100A8+ ICs seem to undergo a dynamic change during breast cancer progression in association with other IC subset infiltration. The prognostic impact of S100A8+ IC infiltration was greater in less immunogenic tumors.
髓源性抑制细胞(MDSCs)通过免疫和非免疫机制在肿瘤进展中发挥重要作用。本研究旨在评估 S100A8 的表达,S100A8 是一种众所周知的 MDSC 标志物,及其在癌前病变和浸润性乳腺癌中的表达意义。通过免疫组织化学评估肿瘤细胞(TCs)和免疫细胞(ICs)中 S100A8 的表达,并评估其与临床病理特征以及其他 IC 亚群包括 CD4+、CD8+和 FOXP3+肿瘤浸润淋巴细胞(TILs)和 PD-L1+ICs 的浸润的关系。在癌前病变和浸润性癌中,TCs 和 ICs 中的 S100A8 表达呈正相关。与癌前病变相比,浸润性癌中 S100A8+ICs 的数量显著更高,但 S100A8+TCs 数量没有差异。S100A8+ICs 的浸润被揭示为癌前病变和浸润性癌的不良预后指标,尤其是在激素受体阳性亚组中。S100A8+ICs 浸润组中 CD4+、CD8+和 FOXP3+TIL 亚群和 PD-L1+ICs 的浸润显著高于 S100A8+ICs(-)组。IC 亚群浸润的综合分析表明,在 PD-L1+IC(-)、CD8+TIL 低和 FOXP3+TIL 低亚组中,S100A8+ICs 的浸润与不良临床结局相关。总之,S100A8+ICs 似乎在乳腺癌进展过程中与其他 IC 亚群浸润一起发生动态变化。在免疫原性较低的肿瘤中,S100A8+IC 浸润的预后影响更大。